Elarex is a Canadian healthcare technology company that specializes in stabilizing biologicals, particularly vaccines, through its proprietary PT120 formulation technology. This innovative platform allows vaccines that typically require storage at -80°C to be effectively stored at 40°C, significantly enhancing their stability and transportability. The technology is adaptable to existing vaccines without the need for special equipment, making it a versatile solution in the biopharmaceutical industry. Founded in 2019, Elarex has established a strong partnership with McMaster University, leveraging their research expertise to advance its product offerings. The company aims to reduce reliance on cold chain logistics, thereby improving access to vaccines and biologics in challenging environments.
Something looks off?